Pulmonary hypertension in children with sickle cell disease

References

• Simonneau G, Robbins IM, Beghetti M et al. Updated clinical classification of pulmonary hypertension. J. Am. Coll. Cardiol.54(Suppl. 1), S43–S54 (2009).
   PubMed Web of Science ®Google Scholar
• Collins FS, Orringer EP. Pulmonary hypertension and cor pulmonale in the sickle hemoglobinopathies. Am. J. Med.73(6), 814–821 (1982).
   PubMed Web of Science ®Google Scholar
• Moser KM, Shea JG. The relationship between pulmonary infarction, cor pulmonale and the sickle states. Am. J. Med.22(4), 561–579 (1957).
   PubMed Web of Science ®Google Scholar
• Dahoui HA, Hayek MN, Nietert PJ et al. Pulmonary hypertension in children and young adults with sickle cell disease: evidence for familial clustering. Pediatr. Blood Cancer54(3), 398–402 (2010).
   PubMed Web of Science ®Google Scholar
• Minniti CP, Sable C, Campbell A et al. Elevated tricuspid regurgitant jet velocity in children and adolescents with sickle cell disease: association with hemolysis and hemoglobin oxygen desaturation. Haematologica94(3), 340–347 (2009).
   PubMed Web of Science ®Google Scholar
• Gordeuk VR, Campbell A, Rana S et al. Relationship of erythropoietin, fetal hemoglobin, and hydroxyurea treatment to tricuspid regurgitation velocity in children with sickle cell disease. Blood114(21), 4639–4644 (2009).
   PubMed Web of Science ®Google Scholar
• Sedrak A, Rao SP, Miller ST, Hekmat V, Rao M. A prospective appraisal of pulmonary hypertension in children with sickle cell disease. J. Pediatr. Hematol. Oncol.31(2), 97–100 (2009).
   PubMed Web of Science ®Google Scholar
• Lee MT, Small T, Khan MA, Rosenzweig EB, Barst RJ, Brittenham GM. Doppler-defined pulmonary hypertension and the risk of death in children with sickle cell disease followed for a mean of three years. Br. J. Haematol.146(4), 437–441 (2009).
   PubMed Web of Science ®Google Scholar
• Liem RI, Nevin MA, Prestridge A, Young LT, Thompson AA. Tricuspid regurgitant jet velocity elevation and its relationship to lung function in pediatric sickle cell disease. Pediatr. Pulmonol.44(3), 281–289 (2009).
   PubMed Web of Science ®Google Scholar
• Pashankar FD, Carbonella J, Bazzy-Asaad A, Friedman A. Prevalence and risk factors of elevated pulmonary artery pressures in children with sickle cell disease. Pediatrics121(4), 777–782 (2008).
   PubMed Web of Science ®Google Scholar
• Onyekwere OC, Campbell A, Teshome M et al. Pulmonary hypertension in children and adolescents with sickle cell disease. Pediatr. Cardiol.29(2), 309–312 (2008).
   PubMed Web of Science ®Google Scholar
• Hagar RW, Michlitsch JG, Gardner J, Vichinsky EP, Morris CR. Clinical differences between children and adults with pulmonary hypertension and sickle cell disease. Br. J. Haematol.140(1), 104–112 (2008).
   PubMed Web of Science ®Google Scholar
• Liem RI, Young LT, Thompson AA. Tricuspid regurgitant jet velocity is associated with hemolysis in children and young adults with sickle cell disease evaluated for pulmonary hypertension. Haematologica92(11), 1549–1552 (2007).
   PubMed Web of Science ®Google Scholar
• Gordeuk V, Minniti CP, Nouraie M et al. Elevated tricuspid regurgitation velocity and decline in exercise capacity over 22 months of follow-up in children and adolescents with sickle cell anemia. Haematologica96(1), 33–40 (2010).
   PubMedGoogle Scholar
• Kato GJ, Onyekwere OC, Gladwin MT. Pulmonary hypertension in sickle cell disease: relevance to children. Pediatr. Hematol. Oncol.24(3), 159–170 (2007).
   PubMed Web of Science ®Google Scholar
• Gladwin MT, Sachdev V, Jison ML et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N. Engl. J. Med.350(9), 886–895 (2004).
   PubMed Web of Science ®Google Scholar
• Ataga KI, Moore CG, Jones S et al. Pulmonary hypertension in patients with sickle cell disease: a longitudinal study. Br. J. Haematol.134(1), 109–115 (2006).
   PubMed Web of Science ®Google Scholar
• Klings ES, Anton Bland D, Rosenman D et al. Pulmonary arterial hypertension and left-sided heart disease in sickle cell disease: clinical characteristics and association with soluble adhesion molecule expression. Am. J. Hematol.83(7), 547–553 (2008).
   PubMed Web of Science ®Google Scholar
• Naoman SG, Nouraie M, Castro OL et al. Echocardiographic findings in patients with sickle cell disease. Ann. Hematol.89(1), 61–66 (2009).
   PubMed Web of Science ®Google Scholar
• van Beers EJ, Nur E, Schaefer-Prokop CM et al. Cardiopulmonary imaging, functional and laboratory studies in sickle cell disease associated pulmonary hypertension. Am. J. Hematol.83(11), 850–854 (2008).
   PubMed Web of Science ®Google Scholar
• Haque AK, Gokhale S, Rampy BA, Adegboyega P, Duarte A, Saldana MJ. Pulmonary hypertension in sickle cell hemoglobinopathy: a clinicopathologic study of 20 cases. Hum. Pathol.33(10), 1037–1043 (2002).
   PubMed Web of Science ®Google Scholar
• Castro O, Hoque M, Brown BD. Pulmonary hypertension in sickle cell disease: cardiac catheterization results and survival. Blood101(4), 1257–1261 (2003).
   PubMed Web of Science ®Google Scholar
• Sutton LL, Castro O, Cross DJ, Spencer JE, Lewis JF. Pulmonary hypertension in sickle cell disease. Am. J. Cardiol.74(6), 626–628 (1994).
   PubMed Web of Science ®Google Scholar
• Fitzhugh CD, Lauder N, Jonassaint JC et al. Cardiopulmonary complications leading to premature deaths in adult patients with sickle cell disease. Am. J. Hematol.85(1), 36–40 (2010).
   PubMed Web of Science ®Google Scholar
• Katzenstein A, Askin F. Pulmonary hypertension and other vascular disorders. In: Surgical Pathology of Non-Neoplastic Lung Disease. 2nd Edition. Bennington (Ed.). Saunders, Philadelphia, PA, USA, 434–457 (1990).
   Google Scholar
• Graham JK, Mosunjac M, Hanzlick RL. Sickle cell lung disease and sudden death: a retrospective/prospective study of 21 autopsy cases and literature review. Am. J. Forensic Med. Pathol.28(2), 168–172 (2007).
   PubMed Web of Science ®Google Scholar
• Kato GJ, McGowan V, Machado RF et al. Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease. Blood107(6), 2279–2285 (2006).
   PubMed Web of Science ®Google Scholar
• Villagra J, Shiva S, Hunter LA, Machado RF, Gladwin MT, Kato GJ. Platelet activation in patients with sickle disease, hemolysis-associated pulmonary hypertension, and nitric oxide scavenging by cell-free hemoglobin. Blood110(6), 2166–2172 (2007).
   PubMed Web of Science ®Google Scholar
• Ambrusko SJ, Gunawardena S, Sakara A et al. Elevation of tricuspid regurgitant jet velocity, a marker for pulmonary hypertension in children with sickle cell disease. Pediatr. Blood Cancer47(7), 907–913 (2006).
   PubMed Web of Science ®Google Scholar
• Walford G, Loscalzo J. Nitric oxide in vascular biology. J. Thromb. Haemost.1(10), 2112–2118 (2003).
   PubMed Web of Science ®Google Scholar
• Reiter CD, Wang X, Tanus-Santos JE et al. Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat. Med.8(12), 1383–1389 (2002).
   PubMed Web of Science ®Google Scholar
• Aslan M, Freeman BA. Oxidant-mediated impairment of nitric oxide signaling in sickle cell disease–mechanisms and consequences. Cell. Mol. Biol. (Noisy-le-grand)50(1), 95–105 (2004).
   PubMed Web of Science ®Google Scholar
• Wood KC, Hebbel RP, Granger DN. Endothelial cell NADPH oxidase mediates the cerebral microvascular dysfunction in sickle cell transgenic mice. FASEB J.19(8), 989–991 (2005).
   PubMed Web of Science ®Google Scholar
• Hsu LL, Champion HC, Campbell-Lee SA et al. Hemolysis in sickle cell mice causes pulmonary hypertension due to global impairment in nitric oxide bioavailability. Blood109(7), 3088–3098 (2007).
   PubMed Web of Science ®Google Scholar
• Morris CR, Kato GJ, Poljakovic M et al. Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. JAMA294(1), 81–90 (2005).
   PubMed Web of Science ®Google Scholar
• Gordeuk VR, Sachdev V, Taylor JG, Gladwin MT, Kato G, Castro OL. Relative systemic hypertension in patients with sickle cell disease is associated with risk of pulmonary hypertension and renal insufficiency. Am. J. Hematol.83(1), 15–18 (2008).
   PubMed Web of Science ®Google Scholar
• De Castro LM, Jonassaint JC, Graham FL, Ashley-Koch A, Telen MJ. Pulmonary hypertension associated with sickle cell disease: clinical and laboratory endpoints and disease outcomes. Am. J. Hematol.83(1), 19–25 (2008).
   PubMed Web of Science ®Google Scholar
• Anthi A, Machado RF, Jison ML et al. Hemodynamic and functional assessment of patients with sickle cell disease and pulmonary hypertension. Am. J. Respir. Crit. Care Med.175(12), 1272–1279 (2007).
   PubMed Web of Science ®Google Scholar
• Koumbourlis AC, Lee DJ, Lee A. Longitudinal changes in lung function and somatic growth in children with sickle cell disease. Pediatr. Pulmonol.42(6), 483–488 (2007).
   PubMed Web of Science ®Google Scholar
• MacLean JE, Atenafu E, Kirby-Allen M et al. Longitudinal decline in lung volume in a population of children with sickle cell disease. Am. J. Respir. Crit. Care Med.178(10), 1055–1059 (2008).
   PubMed Web of Science ®Google Scholar
• Field JJ, Stocks J, Kirkham FJ et al. Airway hyper-responsiveness in children with sickle cell anemia. Chest139(3), 563–568 (2010).
   PubMed Web of Science ®Google Scholar
• Campbell A, Minniti CP, Nouraie M et al. Prospective evaluation of haemoglobin oxygen saturation at rest and after exercise in paediatric sickle cell disease patients. Br. J. Haematol.147(3), 352–359 (2009).
   PubMed Web of Science ®Google Scholar
• Niu X, Nouraie M, Campbell A et al. Angiogenic and inflammatory markers of cardiopulmonary changes in children and adolescents with sickle cell disease. PLoS ONE4(11), e7956 (2009).
   PubMed Web of Science ®Google Scholar
• Ataga KI, Moore CG, Hillery CA et al. Coagulation activation and inflammation in sickle cell disease-associated pulmonary hypertension. Haematologica93(1), 20–26 (2008).
   PubMed Web of Science ®Google Scholar
• Kato GJ, Martyr S, Blackwelder WC et al. Levels of soluble endothelium-derived adhesion molecules in patients with sickle cell disease are associated with pulmonary hypertension, organ dysfunction, and mortality. Br. J. Haematol.130(6), 943–953 (2005).
   PubMed Web of Science ®Google Scholar
• Machado RF, Mack AK, Martyr S et al. Severity of pulmonary hypertension during vaso-occlusive pain crisis and exercise in patients with sickle cell disease. Br. J. Haematol.136(2), 319–325 (2007).
   PubMed Web of Science ®Google Scholar
• Akgul F, Seyfeli E, Melek I et al. Increased QT dispersion in sickle cell disease: effect of pulmonary hypertension. Acta. Haematol.118(1), 1–6 (2007).
   PubMed Web of Science ®Google Scholar
• Mueller BU, Martin KJ, Dreyer W, Bezold LI, Mahoney DH. Prolonged QT interval in pediatric sickle cell disease. Pediatr. Blood Cancer47(6), 831–833 (2006).
   PubMed Web of Science ®Google Scholar
• Gladwin MT, Vichinsky E. Pulmonary complications of sickle cell disease. N. Engl. J. Med.359(21), 2254–2265 (2008).
   PubMed Web of Science ®Google Scholar
• McQuillan BM, Picard MH, Leavitt M, Weyman AE. Clinical correlates and reference intervals for pulmonary artery systolic pressure among echocardiographically normal subjects. Circulation104(23), 2797–2802 (2001).
   PubMed Web of Science ®Google Scholar
• Vachiery JL, Coghlan G. Screening for pulmonary arterial hypertension in systemic sclerosis. Eur. Respir. Rev.18(113), 162–169 (2009).
   PubMedGoogle Scholar
• Sitbon O, Lascoux-Combe C, Delfraissy JF et al. Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era. Am. J. Respir. Crit. Care Med.177(1), 108–113 (2008).
   PubMed Web of Science ®Google Scholar
• McLaughlin VV, Archer SL, Badesch DB et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J. Am. Coll. Cardiol.53(17), 1573–1619 (2009).
   PubMed Web of Science ®Google Scholar
• Machado RF, Anthi A, Steinberg MH et al. N-terminal pro-brain natriuretic peptide levels and risk of death in sickle cell disease. JAMA296(3), 310–318 (2006).
   PubMed Web of Science ®Google Scholar
• Nagaya N, Nishikimi T, Uematsu M et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation102(8), 865–870 (2000).
   PubMed Web of Science ®Google Scholar
• Fijalkowska A, Kurzyna M, Torbicki A et al. Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension. Chest129(5), 1313–1321 (2006).
   PubMed Web of Science ®Google Scholar
• Leight L, Snider TH, Clifford GO, Hellems HK. Hemodynamic studies in sickle cell anemia. Circulation10(5), 653–662 (1954).
   PubMed Web of Science ®Google Scholar
• Miyamoto S, Nagaya N, Satoh T et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am. J. Respir. Crit. Care Med.161(2 Pt 1), 487–492 (2000).
   PubMed Web of Science ®Google Scholar
• Charache S, Terrin ML, Moore RD et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N. Engl. J. Med.332(20), 1317–1322 (1995).
   PubMed Web of Science ®Google Scholar
• Steinberg MH, Barton F, Castro O et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA289(13), 1645–1651 (2003).
   PubMed Web of Science ®Google Scholar
• Ataga KI, Sood N, De Gent G et al. Pulmonary hypertension in sickle cell disease. Am. J. Med.117(9), 665–669 (2004).
   PubMed Web of Science ®Google Scholar
• Pashankar FD, Carbonella J, Bazzy-Asaad A, Friedman A. Longitudinal follow up of elevated pulmonary artery pressures in children with sickle cell disease. Br. J. Haematol.144(5), 736–741 (2009).
   PubMed Web of Science ®Google Scholar
• Olnes M, Chi A, Haney C et al. Improvement in hemolysis and pulmonary arterial systolic pressure in adult patients with sickle cell disease during treatment with hydroxyurea. Am. J. Hematol.84(8), 530–532 (2009).
   PubMed Web of Science ®Google Scholar
• Lee MT, Piomelli S, Granger S et al. Stroke Prevention Trial in Sickle Cell Anemia (STOP): extended follow-up and final results. Blood108(3), 847–852 (2006).
   PubMed Web of Science ®Google Scholar
• Minniti CP, Machado RF, Coles WA, Sachdev V, Gladwin MT, Kato GJ. Endothelin receptor antagonists for pulmonary hypertension in adult patients with sickle cell disease. Br. J. Haematol.147(5), 737–743 (2009).
   PubMed Web of Science ®Google Scholar
• Barst RJ, Mubarak KK, Machado RF et al. Exercise capacity and haemodynamics in patients with sickle cell disease with pulmonary hypertension treated with bosentan: results of the ASSET studies. Br. J. Haematol.149(3), 426–435 (2010).
   PubMed Web of Science ®Google Scholar
• Machado RF, Martyr S, Kato GJ et al. Sildenafil therapy in patients with sickle cell disease and pulmonary hypertension. Br. J. Haematol.130(3), 445–453 (2005).
   PubMed Web of Science ®Google Scholar
• Derchi G, Forni GL, Formisano F et al. Efficacy and safety of sildenafil in the treatment of severe pulmonary hypertension in patients with hemoglobinopathies. Haematologica90(4), 452–458 (2005).
   PubMed Web of Science ®Google Scholar
• Machado RF, Barst RJ, Yovetich NA et al. Evaluation of sildenafil therapy for patients with sickle cell disease and increased tricuspid regurgitant velocity: preliminary results of the Walk-PHaSST trial. Am. J. Respir. Crit. Care Med.181, A2514 (2010).
   Google Scholar
• Rubin LJ. Calcium channel blockers in primary pulmonary hypertension. Chest.88(Suppl. 4), 257S–260S (1985).
   Google Scholar
• Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N. Engl. J. Med.327(2), 76–81 (1992).
   PubMed Web of Science ®Google Scholar
• Klings ES, Farber HW. Current management of primary pulmonary hypertension. Drugs61(13), 1945–1956 (2001).
   PubMed Web of Science ®Google Scholar
• Stein PD, Beemath A, Meyers FA, Skaf E, Olson RE. Deep venous thrombosis and pulmonary embolism in hospitalized patients with sickle cell disease. Am. J. Med.119(10), e897–e811 (2006).
   PubMed Web of Science ®Google Scholar